A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 978-983

  Sanoff, Hanna K ^a,b   Davies, Janine M ^a,b   Walko, Christine ^b   Irvin, William ^a,b   Buie, Larry ^c   Keller, Kimberly ^b   Ivanova, Anastasia ^b   Chiu, Wing Keung ^b   O'Neil, Bert H ^a,b   Stinchcombe, Thomas E ^a,b   Dees, E Claire ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Erlotinib; Influnine; Phase I; Safety and toxicity

Indexed keywords

CYTOCHROME P450 3A4; ERLOTINIB; VINFLUNINE; ANTINEOPLASTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; DRUG DERIVATIVE; QUINAZOLINE DERIVATIVE; VINBLASTINE;

ABDOMINAL PAIN; ADENOID CYSTIC CARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COLORECTAL CANCER; CONSTIPATION; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; ENZYME ACTIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEMALE; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HEART DISEASE; HEART PAIN; HUMAN; HYPERBILIRUBINEMIA; HYPERNATREMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LETHARGY; LEUKOPENIA; LUNG ADENOCARCINOMA; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MOTOR NEUROPATHY; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PAROTID ADENOCARCINOMA; PAROTID GLAND CANCER; PAROTID SQUAMOUS CELL CARCINOMA; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; SKIN DISEASE; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; VOMITING; YAWS; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHENOTYPE; QUINAZOLINES; TREATMENT OUTCOME; VINBLASTINE;

EID: 84856067729     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9427-1     Document Type: Article

References (26)

1. Kruczynski A et al (1998) Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 41(6):437-447
2. Bennouna J et al (2008) Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 14(6):1625-1632
3. Bennouna J et al (2003) Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 14(4):630-637
4. Yun-San Yip A, Yuen-Yuen Ong E, Chow LW (2008) Vinflunine: clinical perspectives of an emerging anticancer agent. Expert Opin Investig Drugs 17(4):583-591
5. Culine S et al (2006) A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94(10):1395-1401
6. Campone M et al (2006) Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 95(9):1161-1166
7. Krzakowski M et al (2007) Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen. J Clin Oncol 25 (18S): (abstr 7511)
8. Talbot DC et al (2007) Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 25(30):4751-4756
9. Hanauske AR et al (1994) Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro. Eur J Cancer 30A (11): 1688-1694
10. Depenbrock H et al (1995) Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro. Invest New Drugs 13(3):187-193
11. Cunningham D et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337-345
12. Huang SM, Harari PM (1999) Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 17(3):259-269
13. Genentech (OSI) Oncology (2004) FDA package insert Tarceva (erlotinib). November 18
14. Burstein HJ et al (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multi-center phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21(15):2889-2895
15. Mahaffey C et al (2007) Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer 8(9):548-553
16. Solit DB et al (2005) Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 11(5):1983-1989
17. Davies AM et al (2006) Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 7(6):385-388
18. Cancer Therapy Evaluation Program (2006) Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. 2003 March 13 (http://ctep. cancer.gov), Publish Date: August 9
19. Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
20. Hirth J et al (2000) The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6(4):1255-1258
21. Kanazawa H et al (2004) Determination of midazolam and its metabolite as a probe for cytochrome P450 3A4 phenotype by liquid chromatography-mass spectrometry. J Chromatogr A 1031:213-218
22. Pujol JL et al (2006) Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. J Thorac Oncol 1(5):417-424
23. Chen YM et al (2007) Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer 109(9):1821-1828
24. Bellmunt J et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol
25. Shah U et al (2008) A phase I trial of pemetrexed and vinflunine (VFL). J Clin Oncol 26 (May 20 suppl; abstr 13508)
26. Stinchcombe TE et al (2008) Preliminary safety and efficacy data of a phase II trial of vinflunine and cetuximab in the second-line treatment of patients with advanced non-small cell lung cancer. J Clin Oncol 26 (May 20 suppl; abstr 19100)